Am J Hematol

1. ATALLAH-YUNES SA, Nze CC, King RL, Rees MJ, et al
   Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies.
   Am J Hematol. 2025 Sep 3. doi: 10.1002/ajh.70058.
   

   >> Share

   
   

   
   Blood

2. HAVRANEK O
   Classic Hodgkin lymphoma: the journey over the destination.
   Blood. 2025;146:1152-1153.
   

   >> Share

   
   
3. TATTERTON DJ, Newby ML, Allen JD, Sale BJ, et al
   The Origin, Diagnosis, and Prognosis of Oligomannose-Type Diffuse Large B-Cell Lymphoma.
   Blood. 2025 Sep 2:blood.2025029163. doi: 10.1182/blood.2025029163.
   

   >> Share

   
   
4. PAL I, Illendula A, Joyner AM, Manavalan JS, et al
   Nanoromidepsin, a Polymer Nanoparticle of the HDAC Inhibitor, Improves Safety and Efficacy in Models of T-cell Lymphoma.
   Blood. 2025 Sep 2:blood.2024027997. doi: 10.1182/blood.2024027997.
   

   >> Share

   
   

   
   BMC Cancer

5. JIN J, Ren S, Zhang W, Yang P, et al
   Patient-reported symptom burden and health-related quality of life in patients with aggressive Non-Hodgkin lymphoma: a cross-sectional study.
   BMC Cancer. 2025;25:1406.
   

   >> Share

   
   

   
   Br J Dermatol

6. GHOSH S, Pavlova O, Latshaw A, Kim D, et al
   Multi-Harmonic Imaging-Based Automated Recognition of Cutaneous T-Cell Lymphoma.
   Br J Dermatol. 2025 Sep 4:ljaf345. doi: 10.1093.
   

   >> Share

   
   

   
   Br J Haematol

7. LUMINARI S, Barbieri E, Nizzoli ME
   Towards a chemo-free approach for follicular lymphoma.
   Br J Haematol. 2025 Aug 30. doi: 10.1111/bjh.70126.
   

   >> Share

   
   
8. KLEINSTERN G, Robinson DP, Abu Seir R, Perlman R, et al
   European-based polygenic risk score and genome-wide association study of B-cell non-Hodgkin lymphoma subtypes in Israeli Jews and Palestinian Arabs.
   Br J Haematol. 2025 Aug 31. doi: 10.1111/bjh.70125.
   

   >> Share

   
   
9. MARIOTTI J, Pinton C, Giordano L, Taurino D, et al
   Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysis.
   Br J Haematol. 2025 Aug 31. doi: 10.1111/bjh.70091.
   

   >> Share

   
   
10. SONG Y, Zou D, Yang H, Wu J, et al
    Two-year follow-up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study.
    Br J Haematol. 2025 Sep 1. doi: 10.1111/bjh.20122.
    

    >> Share

    
    
11. CHAGANTI S, Dulobdas V, Wilson MR, Tucker D, et al
    Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper.
    Br J Haematol. 2025 Sep 5. doi: 10.1111/bjh.70018.
    

    >> Share

    
    

    
    Hum Pathol

12. KIM B, Chae SW, Kim HJ, Roh J, et al
    Comparative analysis of the tumor microenvironment in primary CNS and testicular large B-cell lymphomas using digital image analysis and its implications for immunotherapy.
    Hum Pathol. 2025;163:105874.
    

    >> Share

    
    

    
    Int J Cancer

13. MOORE A, Kane E, Teras LR, Machiela MJ, et al
    Genetically determined body mass index is associated with diffuse large B-cell lymphoma in polygenic and Mendelian randomization analyses.
    Int J Cancer. 2025 Sep 5. doi: 10.1002/ijc.70039.
    

    >> Share

    
    
14. BARNA G, Szaloki G, Mark A, Hunyadi A, et al
    CD86, the double agent: Significance of CD86 expression in B-cell malignancies.
    Int J Cancer. 2025;157:1772-1780.
    

    >> Share

    
    

    
    Leuk Lymphoma

15. SHAH B, Challagulla S, Xu S, Williams R, et al
    Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma.
    Leuk Lymphoma. 2025 Sep 1:1-11. doi: 10.1080/10428194.2025.2541911.
    

    >> Share

    
    

    
    PLoS One

16. THEIL DE, Butow C, Scharf S, Schafer H, et al
    Behavioral investigation of reactive and neoplastic lymphocytes in human lymph nodes in 4D.
    PLoS One. 2025;20:e0331439.
    

    >> Share

    
    

    
    Radiother Oncol

17. BOERSMA LJ, Hessels A, Roberti S, Seravall E, et al
    Selection of patients for proton therapy to reduce risk of second primary lung and breast cancer.
    Radiother Oncol. 2025 Jul 4:110998. doi: 10.1016/j.radonc.2025.110998.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share